Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor

• DOI: 10.1007/s00432-023-04806-y
• Publication Date: 2023-04-28T15:01:57Z
• Authors: Ying Lin; Bo Yu; Haifeng Sun; Hongyu Zhang; Zhihuang Hu; Yao Zhang; Zhenhua Wu; Si Sun; Xinmin Zhao; Hui Yu; Xianghua Wu; Yuan Li; Jialei Wang; Huijie Wang
• Keywords: Hematology

Thoracic SMARCA4-deficient undifferentiated tumor (SD-UT) is a highly aggressive disease that nosologically related to but distinct from non-small cell lung cancer (SD-NSCLC). No standard treatment guidelines were established for SD-UT. This research explored the efficacy of different treatments in SD-UT, and prognostic, clinicopathologic genomic difference between SD-UT SD-NSCLC.Information 25 22 SD-NSCLC patients diagnosed treated Fudan University Shanghai Cancer Center January, 2017 September, 2022 was analyzed.SD-UT similar characteristics onset age, male prevalence, heavy smoking history metastatic pattern. showed rapid relapse pattern after radical therapy. For Stage IV patients, immune checkpoint inhibitor (ICI) plus chemotherapy significantly improved median progression-free survival (PFS) compared traditional as first-line (26.8 vs. 2.73 months, p = 0.0437), while objective response rates two arms comparable (71.4% 66.7%). significant differences observed under settings. or receiving ICI first line had prolonged OS than those with latter lines without throughout clinical courses. Genetic study found frequent SMARCA4, TP53 LRP1B mutations SD-UT.To best our knowledge, this largest series date compare ICI-based document an effective strategy